
    
      This is an investigator-initiated, single site study, consisting of two phases: 8 weeks of
      open label treatment with levetiracetam (500-2000 mg/day) in patients with PTSD, and in those
      who demonstrate at least minimal improvement, 12 weeks of randomized, double-blind treatment
      with either levetiracetam or matching placebo.
    
  